TY  - BOOK
AU  - Lundberg, Ingrid E. 
TI  - A Phase 3 Trial of brepocitinib in dermatomyositis
KW  - ALERGIA
KW  - INMUNOLOGÍA GENERAL
KW  - ENFERMEDAD AUTOINMUNE
KW  - DERMATOLOGÍA GENERAL
KW  - ENFERMEDAD PULMONAR INTERSTICIAL
KW  - ENFERMEDAD NEUROMUSCULAR
KW  - NEUROLOGÍA
KW  - NEUROCIRUGÍA
KW  - CÉLULAS T
N2  - Dermatomyositis is a subgroup of idiopathic inflammatory myopathies — systemic autoimmune disorders that are typically characterized by the involvement of multiple organs, including muscle, skin, joints, lungs, gastrointestinal tract, and heart — all conditions with high morbidity and mortality. Treatment of myositis is based on off-label use of high doses of glucocorticoids, usually over long periods of time, in combination with immune-modulating agents and physical exercise. However, the outcome is often disappointing, with persisting inflammation and recurrent flares
ER  -